Table 3 Coefficient of Univariate analysis by cox regression analysis of relapse during observation for patients without anti-allergy therapy.

From: Corticosteroid reduction by addition of cetirizine and montelukast in biopsy-proven minimal-change nephrotic syndrome concomitant with allergic disorders

Variable

Hazard ratio

Lower 95% CI

Upper 95% CI

p value

Past relapse per year, 1 time per year

37.6

2.5

568.5

0.009

Immunosupressant, yes

4.0

1.2

13.2

0.022

Age, 10 years

0.67

0.47

0.97

0.032

Disease duration, 1 year

0.97

0.92

1.02

0.26

Urinary protein, 1 g/gCre

0.28

0.00

37.0

0.61

eGFR, 1 ml/min/1.73 m2

1.01

0.97

1.04

0.81

Minimum PSL dose, 1 mg

1.03

0.84

1.26

0.78

Concomitant allergic disorders, yes

1.08

0.33

3.57

0.89

PSL dose at baseline, 1 mg

1.11

0.95

1.29

0.18

Dyslipedemia, yes

0.54

0.14

2.03

0.36

Hyperurecemia, yes

0.75

0.10

5.87

0.78

Hypertension, yes

1.04

0.32

3.42

0.94

Diabetes mellitus, yes

1.77

0.54

5.81

0.35

Infection, irregular corticosteroid reduction, or malignancy, yes

1.40

0.30

6.46

0.67

IgE, 1 U/mL

1.00

1.00

1.00

0.40

Eos, 1/microg

1.00

1.00

1.00

0.52

  1. Coefficients of univariate Cox regression analysis of relapse during observation in the control group.
  2. Past relapse per year, use of immunosuppressants, and age were statistically associated with relapse.
  3. Cre, creatinine; eGFR, estimated glomerular filtration rate; PSL, prednisolone; CI, confidence interval.
Back to article page